Table 1. A summary of subject characteristics in our discovery cohort.
| Subject Characteristic | BPD | MDD | Control | Total Sample |
| Sample number | 30 | 30 | 30 | 90 |
| Age (mean, (SD))* | 53.10 (14.17) | 41.23 (12.53) | 52.40 (14.35) | 48.91 (14.62) |
| Males (n) | 10 | 10 | 9 | 29 |
| Females (n) | 20 | 20 | 21 | 61 |
| BMI (mean, (SD)) | 26.66 (5.51) | 25.90 (4.11) | 24.93 (3.33) | 25.83 |
| Cardiovascular Problem (n)* | 8 | 1 | 5 | 14 |
| Diabetes (n) | 2 | 0 | 2 | 4 |
| Antidepressants (n) | 6 | 30 | 0 | 36 |
| Lithium (n) | 20 | 0 | 0 | 20 |
| Carbamazepine (n) | 3 | 0 | 0 | 3 |
| Sodium valproate (n) | 3 | 0 | 0 | 3 |
| Antipsychotics (n) | 16 | 0 | 0 | 16 |
This includes general characteristics (total number in each subject group, age, number of males, number of females), information about co-morbidity (body mass index (BMI), number with diabetes, number with cardiovascular problems), and current medication use (antidepressants, antipsychotics, lithium, carbamazepine, and sodium valproate). Note: cardiovascular problems is an umbrella term consisting of those subjects who reported high levels of cholesterol, high blood pressure, or a history of angina or heart attacks. For age, males (n), females (n), BMI, cardiovascular problems (n), and diabetes (n) we performed ANOVA to assess differences between groups. Significant differences between groups (p≤0.05) is indicated with a *. [Age: F(2, 87) = 7.077, p = 0.001; Cardiovascular Problems: F(2, 87) = 3.252, p = 0.043].